A panel medical oncologists provide an overview of circulating tumor DNA and its role in MRD (minimal residual disease) testing in the treatment of patients with colorectal cancer.
Next-Generation ColoAlert Screening Test Shows High Sensitivity, Specificity for CRC and Adenoma Detection
Lunning and Rutherford Detail Considerations for BV-AVD Use in Older Patients With Hodgkin Lymphoma
HER2 Expression May Hold the Key to Predicting Survival Outcomes in CRC
Gutierrez and Leslie Discuss Recent Efforts and Future Advances in CAR T-Cell Therapy
Early Data With Copanlisib/Nivolumab Combo Support Further Exploration in MSS CRC
Updated Phase 1 Data Support Further Research of Botensilimab/Balstilimab in Refractory MSS CRC
Navigating the Intersection of Radiation Therapy and Immunotherapy in Endometrial Cancer
As Orthopedic Oncology Evolves, Caring for the Clinician Must Be a Priority
Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD
Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma